Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Analysts have assigned an average rating of "Buy" for Catalyst Pharmaceuticals (NASDAQ:CPRX), with five recommending a buy and two a strong buy, reflecting positive market sentiment.
• The average target price for Catalyst Pharmaceuticals shares is $33.20, showing a strong potential upside based on recent analyst evaluations.
• Insider and institutional trading activity is notable, with insider Preethi Sundaram selling shares and various institutional investors significantly increasing their stakes in the company.

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $33.20.

CPRX has been the subject of several recent research reports. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $20.19 on Thursday. Catalyst Pharmaceuticals has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The company has a market cap of $2.47 billion, a PE ratio of 12.24, a P/E/G ratio of 0.83 and a beta of 0.70. The business has a 50-day simple moving average of $21.97 and a two-hundred day simple moving average of $22.73.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.40% of the company's stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. LPL Financial LLC lifted its position in Catalyst Pharmaceuticals by 38.0% during the 4th quarter. LPL Financial LLC now owns 57,983 shares of the biopharmaceutical company's stock worth $1,210,000 after acquiring an additional 15,961 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 162.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 64,395 shares of the biopharmaceutical company's stock valued at $1,344,000 after buying an additional 39,836 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Catalyst Pharmaceuticals by 1.4% in the 4th quarter. Russell Investments Group Ltd. now owns 176,259 shares of the biopharmaceutical company's stock valued at $3,679,000 after buying an additional 2,471 shares during the period. Bank of Montreal Can lifted its holdings in shares of Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 875 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Legal & General Group Plc now owns 344,623 shares of the biopharmaceutical company's stock valued at $7,192,000 after buying an additional 9,741 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.